Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Summit Therapeutics (SMMT) Asset Writedowns and Impairment (2020 - 2023)

Summit Therapeutics' Asset Writedowns and Impairment history spans 2 years, with the latest figure at $474000.0 for Q1 2023.

For Q1 2023, Asset Writedowns and Impairment changed N/A year-over-year to $474000.0; the TTM value through Dec 2023 reached $474000.0, changed N/A, while the annual FY2023 figure was $474000.0, N/A changed from the prior year.
Asset Writedowns and Impairment reached $474000.0 in Q1 2023 per SMMT's latest filing, down from $859000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $859000.0 in Q3 2020 to a low of $474000.0 in Q1 2023.